Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2009

01-10-2009 | Original Article

Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort

Authors: Taku Inoue, Kunitoshi Iseki, Chiho Iseki, Yusuke Ohya, Kozen Kinjo, Shuichi Takishita

Published in: Clinical and Experimental Nephrology | Issue 5/2009

Login to get access

Abstract

Background

High heart rate and chronic kidney disease (CKD) are both risk factors for cardiovascular morbidity and mortality. The relationship between heart rate and the risk of developing CKD, however, has not been studied in a large screened cohort.

Methods and results

We examined the relationship between heart rate and the risk of developing CKD in participants in a health evaluation program. CKD was diagnosed as glomerular filtration rate of less than 60 mL/min/1.73 m2, calculated using the Modification of Diet in Renal Disease (MDRD) study equation or dipstick proteinuria. Among 7,958 subjects, 1,199 subjects diagnosed with CKD or with arrhythmia at baseline examination were excluded. A total of 6,759 subjects (4,268 men, 2,491 women, 20–84 years of age) were evaluated. The subjects were quadrisected according to baseline heart rate. The subjects were followed up for a mean of 47 ± 16 months (range 7–71 months). Seven hundred and thirty-four subjects developed CKD over the 5-year follow-up period. Subjects with a high heart rate had greater magnitude of decreasing glomerular filtration rate (eGFR) and higher odds ratio of developing proteinuria. Cox analysis indicated that each heart rate category increment led to approximately 1.1 times increase in the risk of developing CKD, eGFR less than 60 mL/min/1.73 m2, and 1.2 times increase of the risk of developing proteinuria in middle-aged or older subjects.

Conclusions

High heart rate is a risk factor for developing CKD in middle-aged or older subjects.
Literature
1.
go back to reference Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489–94.CrossRefPubMed Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113:1489–94.CrossRefPubMed
2.
go back to reference Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 1991;121:172–7.CrossRefPubMed Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J. 1991;121:172–7.CrossRefPubMed
3.
go back to reference Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med. 1999;159:585–92.CrossRefPubMed Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med. 1999;159:585–92.CrossRefPubMed
4.
go back to reference Fujiura Y, Adachi H, Tsuruta M, Jacobs DR Jr, Hirai Y, Imaizumi T. Heart rate and mortality in a Japanese general population: an 18-year follow-up study. J Clin Epidemiol. 2001;54:495–500.CrossRefPubMed Fujiura Y, Adachi H, Tsuruta M, Jacobs DR Jr, Hirai Y, Imaizumi T. Heart rate and mortality in a Japanese general population: an 18-year follow-up study. J Clin Epidemiol. 2001;54:495–500.CrossRefPubMed
5.
go back to reference Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.CrossRefPubMed Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.CrossRefPubMed
6.
go back to reference Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180–8.CrossRefPubMed Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180–8.CrossRefPubMed
7.
go back to reference Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800–5.CrossRefPubMed Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800–5.CrossRefPubMed
8.
go back to reference Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.CrossRefPubMed Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.CrossRefPubMed
9.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRefPubMed
10.
go back to reference Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–63.CrossRefPubMed Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–63.CrossRefPubMed
11.
go back to reference Inoue T, Oshiro S, Iseki K, Tozawa M, Touma T, Ikemiya Y, et al. High heart rate relates to clustering of cardiovascular risk factors in a screened cohort. Jpn Circ J. 2001;65:969–73.CrossRefPubMed Inoue T, Oshiro S, Iseki K, Tozawa M, Touma T, Ikemiya Y, et al. High heart rate relates to clustering of cardiovascular risk factors in a screened cohort. Jpn Circ J. 2001;65:969–73.CrossRefPubMed
12.
go back to reference Iseki K, Kohagura K, Sakima A, Iseki C, Kinjo K, Ikemiya Y, et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res. 2007;30:55–62.CrossRefPubMed Iseki K, Kohagura K, Sakima A, Iseki C, Kinjo K, Ikemiya Y, et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res. 2007;30:55–62.CrossRefPubMed
13.
go back to reference Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.CrossRefPubMed Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.CrossRefPubMed
14.
go back to reference Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2001;37:S66–70.CrossRefPubMed Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2001;37:S66–70.CrossRefPubMed
15.
16.
go back to reference Inoue T, Iseki K, Iseki C, Ohya Y, Kinjo K, Takishita S. Association between heart rate and multiple risk factor syndrome. Circ J. 2008;72:454–7.CrossRefPubMed Inoue T, Iseki K, Iseki C, Ohya Y, Kinjo K, Takishita S. Association between heart rate and multiple risk factor syndrome. Circ J. 2008;72:454–7.CrossRefPubMed
17.
go back to reference Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRefPubMed Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.CrossRefPubMed
18.
go back to reference Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol. 2004;15:524–37.CrossRefPubMed Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol. 2004;15:524–37.CrossRefPubMed
19.
go back to reference Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol. 2006;26:232–44.CrossRefPubMed Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol. 2006;26:232–44.CrossRefPubMed
20.
go back to reference Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int Suppl. 2000;75:S7–14.CrossRefPubMed Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int Suppl. 2000;75:S7–14.CrossRefPubMed
21.
go back to reference Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–8.CrossRefPubMed Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–8.CrossRefPubMed
22.
go back to reference Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41:1341–5.CrossRefPubMed Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41:1341–5.CrossRefPubMed
23.
go back to reference Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002;62:956–62.CrossRefPubMed Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002;62:956–62.CrossRefPubMed
24.
go back to reference Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–74.CrossRefPubMed Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–74.CrossRefPubMed
25.
go back to reference Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol. 2006;17:S81–5.CrossRefPubMed Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol. 2006;17:S81–5.CrossRefPubMed
26.
go back to reference Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211–7.PubMed Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211–7.PubMed
27.
go back to reference Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int. 2002;62:1743–9.CrossRefPubMed Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int. 2002;62:1743–9.CrossRefPubMed
28.
go back to reference Keane WF, O’Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol. 1993;4:187–94.PubMed Keane WF, O’Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol. 1993;4:187–94.PubMed
29.
go back to reference Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–40.CrossRefPubMed Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–40.CrossRefPubMed
30.
go back to reference Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, Kinjo K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007;30:937–43.CrossRefPubMed Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, Kinjo K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res. 2007;30:937–43.CrossRefPubMed
31.
go back to reference Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12:1–8.CrossRefPubMed Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol. 2008;12:1–8.CrossRefPubMed
32.
go back to reference Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.CrossRefPubMed Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.CrossRefPubMed
33.
go back to reference Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension. 1997;30:1267–73.CrossRefPubMed Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension. 1997;30:1267–73.CrossRefPubMed
34.
go back to reference Palatini P. Need for a revision of the normal limits of resting heart rate. Hypertension. 1999;33:622–5.CrossRefPubMed Palatini P. Need for a revision of the normal limits of resting heart rate. Hypertension. 1999;33:622–5.CrossRefPubMed
35.
go back to reference Inoue T, Iseki K, Iseki C, Kinjo K, Ohya Y, Takishita S. Heart rate as a risk factor for development of chronic kidney disease—the longitudinal analysis of the screened cohort. J Am Soc Nephrol. 2007;18:313A. Inoue T, Iseki K, Iseki C, Kinjo K, Ohya Y, Takishita S. Heart rate as a risk factor for development of chronic kidney disease—the longitudinal analysis of the screened cohort. J Am Soc Nephrol. 2007;18:313A.
Metadata
Title
Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort
Authors
Taku Inoue
Kunitoshi Iseki
Chiho Iseki
Yusuke Ohya
Kozen Kinjo
Shuichi Takishita
Publication date
01-10-2009
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2009
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0193-3

Other articles of this Issue 5/2009

Clinical and Experimental Nephrology 5/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.